title: Radiotherapy for metastatic carcinomas of the kidney or melanomas: an analysis using palliative end points.
abstract: OBJECTIVE
  To assess the rate and duration of response to palliative radiotherapy (RT) in patients with metastatic melanoma or renal cell carcinoma.
  
  
  METHODS
  From 1992 to 1995, 90 patients were entered into a nonrandomized study. Goals of palliative RT were prospectively defined and subjective response was documented at the end of RT, after 2-6 weeks, and every 3 months thereafter. Most patients were treated with 5 x 4 Gy or 10 x 3 Gy.
  
  
  RESULTS
  Relief of pain from bone lesions was observed in 26 of 40 cases, with a duration of response of 2.4 months, corresponding to 57% of the remaining lifetime. A total of 55% of patients with persistent neurologic dysfunction despite corticosteroids improved, for a duration of 2.5 months (86% of the further lifespan). Freedom from symptoms in patients treated for impending neurological complications from metastases to the brain, spine, or nerve plexus was documented for 86-100% of their lifetime.
  
  
  CONCLUSIONS
  Despite the methodological flaws discussed, the efficacy of a short course of palliative RT for so-called radioresistant tumors is demonstrated.
authors.affiliation: Department of Radiation Oncology, University Hospital Zurich, Switzerland.
authors.forename: P U
authors.initials: PU
authors.lastname: Huguenin
authors.forename: S
authors.initials: S
authors.lastname: Kieser
authors.forename: C
authors.initials: C
authors.lastname: Glanzmann
authors.forename: R
authors.initials: R
authors.lastname: Capaul
authors.forename: U M
authors.initials: UM
authors.lastname: Lütolf
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000532:radiotherapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000532:radiotherapy*; D008545:Melanoma / Q000532:radiotherapy*; D008875:Middle Aged; D010166:Palliative Care; D011446:Prospective Studies; D013125:Spinal Neoplasms / Q000532:radiotherapy / Q000556:secondary